{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"18"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"16"}]}],"title":"Any AE possibly related to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"}]}],"title":"Any AE of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"13"}]}],"title":"Any AE of CTCAE grade 3 or higher, possibly related to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Any AE with outcome = death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Any AE with outcome = death, possibly related to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"}]}],"title":"Any SAE (including events with outcome = death)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"8"}]}],"title":"Any SAE (including events with outcome = death), possibly related to treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"The safety and tolerability of AZD4573 was assessed.","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety set included all participants who received at least 1 dose of any study intervention.","reportingStatus":"POSTED","timeFrame":"From treatment period (Cycle 1) to follow up visit (30 [± 7] ) days from the last dose (upto 26 months).","title":"Number of Participants With Adverse Events (AE) and Serious AEs (SAE)","type":"SECONDARY","unitOfMeasure":"Participants"}